Emily Mullin

Biography for Emily Mullin

Emily Mullin, Associate Editor

Before joining the Fierce life sciences team as an associate editor, Emily Mullin was a reporter at the Baltimore Business Journal, where she covered the healthcare and biotechnology industries, and a staff writer for Dorland Health, a healthcare trade publishing company based in Rockville, MD. She has served as a contributing writer to The Maryland Daily Record, where she’s covered topics ranging from neuroscience to hospital consolidation. Her business and healthcare stories have also appeared in Nephrology Times, Columbus Business First and the Cincinnati Business Courier. She is based in Washington, DC, and is a graduate of the E.W. Scripps School of Journalism at Ohio University. You can contact her at emullin@fiercemarkets.com and follow her on Twitter at @EmilyMFierce.

Articles by Emily Mullin

Inhaled Ebola vaccine may provide higher protection rate

A breathable, respiratory vaccine to guard against Ebola is the latest contender to join the race toward a treatment or vaccine to stop the spread of the deadly virus. Developed by researchers at the University of Texas at Austin, the vaccine has shown that a single dose of the vaccine showed long-term protection in monkeys.

Glaxo hep C vaccine delivers promising early results

Next-generation hepatitis C drugs may be breaking revenue records now, but eventually a vaccine to prevent the disease could cut into the cash cows' market share. That candidate might come from GlaxoSmithKline, whose hepatitis C vaccine just passed an early test, generating strong and broad immune responses not seen before against the transmissible liver disease.

South African trial renews hopes in failed HIV vaccine combo

An HIV vaccine regimen that failed in a notable clinical trial conducted in Thailand has been given a new chance to prove itself.

Ebola update: Novavax testing nanoparticle jab, Glaxo gets EMA's advice

With several companies now expediting Ebola vaccines in an attempt to halt the spread of the deadly virus, Novavax has jumped in the race, announcing that it's using its nanoparticle vaccine technology to advance a candidate of its own.

Ebola roundup: J&J invests $200M in R&D, Glaxo says vaccine will come too late

As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.

Sanofi inks pact with Immune Design to boost herpes vax effort

Sanofi may be trailing in the sprint toward a herpes vaccine, but a new collaboration may give it the boost it needs to stay in the game.

NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali

The race is on to test an experimental Ebola vaccine as West Africa grapples with an out-of-control outbreak and the U.S. scrambles to rectify breaches in protocol after a patient with the virus died at a Dallas hospital and a healthcare worker tested positive for the infection.

Study: Adult TB vaccine with low protection rate better than infant jab

A new study suggests that a tuberculosis vaccine with low efficacy in adolescents and adults could be more successful at reducing rates of the disease than a vaccine intended for infants.

Pfizer's meningitis B vaccine is effective when given with HPV jab

Hoping to boost its chances of FDA approval early next year, Pfizer has unveiled results from a Phase II clinical trial for its meningitis B vaccine, showing that the jab is safe and effective in adolescents when given alongside a licensed vaccine for human papillomavirus.

GSK may give Ebola vaccine to West African healthcare workers in early 2015

As the Ebola outbreak continues to ravage Liberia, Guinea and Sierra Leone, GlaxoSmithKline said Phase I trials of its experimental Ebola vaccine are expected to start in West Africa in the next few weeks, and Phase II trials are likely to begin in early 2015.

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • next ›
  • last »